SI-BONE, Inc. (SIBN)
- Zacks
Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 50%: Here's is How to Trade
The mean of analysts' price targets for Si-Bone (SIBN) points to a 49.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- Zacks
Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates
Si-Bone (SIBN) delivered earnings and revenue surprises of -10.20% and 1.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
SI-BONE, Inc. Reports Financial Results for the Second Quarter 2022
SANTA CLARA, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended June 30, 2022. Recent Highlights Record worldwide revenue of $25.6 million for the second quarter 2022, representing approximately 15% increase over the corresponding period in 2021Record U.S. revenue of $23.8 million for the second quarter 2022, representing a
